FibroGen Inc Banner Image

FibroGen Inc

  • Ticker FGEN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
FibroGen Inc Logo Image
  • 201-500 Employees
  • Based in San Francisco, California
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing roxadustat, or FG-4592, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; FG-3019More, a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage.
4.8 / 5.0 (151)

FibroGen Inc reports have an aggregate usefulness score of 4.8 based on 151 reviews.

FibroGen Inc

Most Recent Annual Report

FibroGen Inc
MOST RECENT 2022 Annual Report and Form 10K

FibroGen Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

FibroGen Inc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!